Millipore, the US-based provider of technologies, tools and services for bioscience research and biopharmaceutical manufacturing, is taking its biopharmaceutical services into Europe with the acquisition of European specialist BioAnaLab.

No price was disclosed for the acquisition, which Millipore said would also reinforce its position as a preferred outsource partner to the biopharmaceutical industry. Based in Oxford, UK, BioAnaLab is a spin-out from the University of Oxford that offers a broad range of services to help clients understand the safety and efficacy of biologic drugs in development.

These services include include assay transfer/development, validation and sample analysis, pharmacokinetics/ toxicokinetics, immunogenicity, biological potency, and vaccine services. Millipore brings to the table “substantial expertise” in biomarker analytical services to strengthen BioAnaLab’s offering in that area, the US company noted.

“As an increasing number of biologics enter the pipeline, companies are leveraging Millipore’s ligand binding assay expertise to help them evaluate the efficacy of these drugs and achieve regulatory compliance,” commented Jonathan DiVincenzo, president of Millipore’s Bioscience Division.

“Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market.”

As part of the acquisition package, Dr Geoff Hale, founder and chief executive officer of BioAnaLab, is joining Millipore as director of biopharma services in Europe.